Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers

A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years

Randomized, observer-blinded, multicenter, dose-escalation Phase 1 clinical study investigating three dose levels of VLA1553 after a single immunization.

120 study participants will be enrolled into the study to receive three different doses (30 subjects in the low and medium and 60 subjects in the high dose group). Vaccination will be given intramuscularly on Day 0. As safety precaution, the study will begin with enrolment of 20 sentinel subjects in an open-label fashion. Thereafter, subjects will be enrolled in a blinded, randomized manner in the three study arms.

A re-vaccination will be given at Month 6 or Month 12 to confirm that a single vaccination will be sufficient to induce high titer neutralizing antibodies and protect subjects from CHIKV viremia.

Study participants will be followed up until 13 months after initial vaccination.

Study Overview

• Status: Completed
• Conditions: Chikungunya
• Intervention / Treatment: Biological: VLA1553

• Study Type: Interventional
• Enrollment (Actual): 120
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Huntsville, Alabama, United States, 35802
      • Optimal Research, LLC
  • Illinois
    • Peoria, Illinois, United States, 61614
      • Optimal Research, LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Aged 18 to 45 years on the Day of screening;
• Has a BMI of ≥ 18.5 and < 30 kg/m2 on the Day of screening;
• Understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to any study-related procedures;
• Generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests;

• If female, subject is of non-childbearing potential. The definition of non-childbearing potential includes the following:

  1. Surgically sterile (e.g., hysterectomy with or without oophorectomy; fallopian tube ligation; endometrial ablation), at least 30 days prior to signature of the Informed Consent form;
  2. At least 5 years post-menopause (i.e., 6 years post last menstrual period), or menopause confirmed by follicle-stimulating hormone (FSH) testing.

Exclusion Criteria:

• History of known CHIKV infection;
• Plans to travel to areas with active CHIKV transmission during the course of the study or history of travel to an endemic CHIKV area within 4 weeks prior to study enrollment;
• Participation in a clinical study involving an investigational CHIKV vaccine;
• Receipt of an inactivated vaccine within 4 weeks or live vaccine within 8 weeks prior to vaccination in this study;
• Positive test results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV);
• (1) Abnormal laboratory liver function values (≥ grade 1), (2) any grade 1 abnormal lab values deemed clinically relevant by the Investigator, and (3) any ≥ grade 2 abnormal lab values irrespective of clinical significance at screening;
• Clinically significant abnormal ECG at screening;
• History of significant cardiovascular, respiratory (including asthma), metabolic, neurological, hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder;
• History of immune-mediated or clinically significant arthritis/arthralgia;
• History of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision that is considered to have achieved a cure;
• Disease or recent or current treatment that can be expected to influence immune response as specified in the protocol;
• History of severe hypersensitivity reactions or anaphylaxis;
• History of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known contraindications);
• Acute febrile infections within two weeks prior to vaccination;
• Subject is of childbearing potential or lactating at the time of enrollment;
• Blood donation within 30 days or receipt of blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or during the course of the study;
• A rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating;
• Known or suspected problem with alcohol or drug abuse as determined by the Investigator;
• Any condition that, in the opinion of the Investigator, may compromise the subjects well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
• Participation in another clinical study involving an investigational medicinal product within 30 days prior to study enrollment or during the course of this study;
• Member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: VLA1553 low dose; VLA1553 with 3.2x10^3 TCID50/ 100 µL (microliter). Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL (milliliter)	Biological: VLA1553; I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
Active Comparator: VLA1553 medium dose; VLA1553 with 3.2x10^4 TCID50/ 1 mL Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL	Biological: VLA1553; I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
Active Comparator: VLA1553 high dose; VLA1553 with 3.2x10^5 TCID50/ 1 mL Re-vaccination at Month 6 or Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL	Biological: VLA1553; I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of solicited injection site reactions	Any measurable injection site reaction will be measured by size and includes injection site pain, tenderness, erythema/redness, induration and swelling.	up to Day 14 after single vaccination
Severity of solicited injection site reactions	Any measurable injection site reaction will be measured by size and includes injection site pain, tenderness, erythema/redness, induration and swelling. They will be rated according to the Severity Grading Scale of Injection Site Reactions (FDA Guidance on Toxicity Grading Scales for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA 2007)	up to Day 14 after single vaccination
Frequency of solicited systemic reactions	Systemic reactions including fever, nausea/vomiting, headache, fatigue, myalgia (muscle pain), arthralgia (joint pain) and rash will be reported in a standardized manner	up to Day 14 after single vaccination
Severity of solicited systemic reactions	Systemic reactions including fever, nausea/vomiting, headache, fatigue, myalgia (muscle pain), arthralgia (joint pain) and rash will be reported in a standardized manner. They will be rated according to the FDA Guidance on Toxicity Grading Scales	up to Day 14 after single vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of any adverse event (AE)		until Day 14, Day 28 and throughout the study period
Severity of any adverse event (AE)	The investigator will assess the severity of AEs using his/her clinical expertise and judgment based on the most appropriate description (mild, moderate, severe) as per study protocol	until Day 14, Day 28 and throughout the study period
Frequency of solicited injection site reactions	Any measurable injection site reaction will be measured by size and includes injection site pain, tenderness, erythema/redness, induration and swelling.	until Day 14, Day 28 and throughout the study period
Severity of solicited injection site reactions	Any measurable injection site reaction will be measured by size and includes injection site pain, tenderness, erythema/redness, induration and swelling. They will be rated according to the Severity Grading Scale of Injection Site Reactions (FDA Guidance on Toxicity Grading Scales for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (FDA 2007)	until Day 14, Day 28 and throughout the study period
Frequency of solicited systemic reactions	Systemic reactions including fever, nausea/vomiting, headache, fatigue, myalgia (muscle pain), arthralgia (joint pain) and rash will be reported in a standardized manner	until Day 14, Day 28 and throughout the study period
Severity of solicited systemic reactions	Systemic reactions including fever, nausea/vomiting, headache, fatigue, myalgia (muscle pain), arthralgia (joint pain) and rash will be reported in a standardized manner. They will be rated according to the FDA Guidance on Toxicity Grading Scales	until Day 14, Day 28 and throughout the study period
Assessment of viremia after each vaccination	Assessment of CHIKV viremia will be done by RT (real-time)-qPCR (quantitative polymerase chain reaction) in blood and urine	on Days 3, 7, 14 and beyond Day 14 after re-vaccination
Immune response as measured by CHIKV-specific neutralizing antibody titer as determined by micro-neutralization (μNT) assay.		Day 28, Day 84, Month 6, Month 12, and 28 days after re-vaccination

Collaborators and Investigators

• Sponsor: Valneva Austria GmbH
• Investigators: Study Chair: Nina Wressnigg, Valneva Austria GmbH

Publications and helpful links

General Publications

• Wressnigg N, Hochreiter R, Zoihsl O, Fritzer A, Bezay N, Klingler A, Lingnau K, Schneider M, Lundberg U, Meinke A, Larcher-Senn J, Corbic-Ramljak I, Eder-Lingelbach S, Dubischar K, Bender W. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect Dis. 2020 Oct;20(10):1193-1203. doi: 10.1016/S1473-3099(20)30238-3. Epub 2020 Jun 1.

Study record dates

Study Major Dates

• Study Start (Actual): March 5, 2018
• Primary Completion (Actual): July 13, 2018
• Study Completion (Actual): July 28, 2019

Study Registration Dates

• First Submitted: December 12, 2017
• First Submitted That Met QC Criteria: December 18, 2017
• First Posted (Actual): December 26, 2017

Study Record Updates

• Last Update Posted (Actual): August 29, 2019
• Last Update Submitted That Met QC Criteria: August 28, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Keywords: CHIKV; Chikungunya; VLA1553; Live-attenuated Chikungunya virus vaccine
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Arbovirus Infections; Vector Borne Diseases; Alphavirus Infections; Togaviridae Infections; Chikungunya Fever
• Other Study ID Numbers: VLA1553-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No